ACTG356--ZDV/3TC/NEVIRAPINE &ZDV/3TC/NEVIRAPINE/159U89 COMBINATION THERAPY

ACTG356--ZDV/3TC/奈韦拉平

• 批准号: 6441985
• 负责人: Kenneth McIntosh
• 金额: $ 2.88万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6441985
• 关键词: AIDS therapy; HIV infections; Retroviridae; clinical research; clinical trial phase I; combination chemotherapy; human subject; human therapy evaluation; lamivudine; microorganism disease chemotherapy; nevirapine; newborn human (0-6 weeks); pediatric AIDS; reverse transcriptase inhibitors; vertical transmission; virus load; zidovudine

Phase I/II trial of three reverse taranscriptase inhibitors in the treatment of very young, vertically HIV-infected infants, with the aim of suppressing viral production maximally at a time very shortly after infection, or as soon as practically possible. There are two cohorts, but in both instances, it can be expected that the child's virus will be oligoclonal and the level of production will be very high (RNA viral loads of 5-6 logs/ml).

三种反向 taranscriptase 抑制剂治疗非常年幼、垂直感染 HIV 的婴儿的 I/II 期试验，目的是在感染后不久或尽快最大程度地抑制病毒产生。有两个队列，但在这两种情况下，可以预期孩子的病毒将是寡克隆的，并且生产水平将非常高（RNA 病毒载量为 5-6 个日志/毫升）。